Compare Organon & Co. Common Stock (OGN) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Southern Copper Corp — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Southern Copper Corp trades at $199.78 (market cap $175.13B). The key difference: Southern Copper Corp is far larger — about 48.4× Organon & Co. Common Stock's market cap, and Southern Copper Corp pays the higher dividend (2.12%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Southern Copper Corp for 62 Days on average.
| OGN | SCCO | |
|---|---|---|
Market Cap | $3.62B | $175.13B |
Volume | 2,892,999 | 611,484 |
Sector | Health | Basic Materials |
52-Week High | $13.81 | $219.70 |
52-Week Low | $5.70 | $120.02 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $11.04B | $176.43B |
Dividend Yield | 0.58% | 2.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Southern Copper (SCCO) trades at $200.68, down 3.84% on the day, but maintains strong fundamentals with impressive earnings beats and robust profitability metrics. The company shows consistent revenue growth from $10.0B in 2022 to $13.4B in 2025, with net income margins expanding to 35.87%. Technical indicators show a bullish trend with support at $204 and resistance at $210, while analyst sentiment remains divided with a consensus price target of $165.60.
SCCO presents a mixed investment case with exceptional profitability and growth prospects from its Mexican projects, but faces valuation concerns with a P/E of 31.12 and divided analyst ratings. Key risks include copper price volatility and execution challenges, while institutional interest remains active with recent purchases by Virginia Retirement Systems.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
